Review article · 2023 · Open access
Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective
Clinical Pharmacology & Therapeutics, 114(4), 751–767 · Published 29 July 2023 · DOI 10.1002/cpt.2988
In brief
“Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective” is a 2023 review article by Rui Zhu and 15 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 51 citations as of 22 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Clinical Pharmacology & Therapeutics.
- Citations
- 51
- Most cited in
- 2026 (17)
- Field-weighted impact
- 2.20
- References
- 53
- Authors
- 16
Abstract
Since the 21st Century Cures Act was signed into law in 2016, real-world data (RWD) and real-world evidence (RWE) have attracted great interest from the healthcare ecosystem globally. The potential and capability of RWD/RWE to inform regulatory decisions and clinical drug development have been extensively reviewed and discussed in the literature. However, a comprehensive review of current applications of RWD/RWE in clinical pharmacology, particularly from an industry perspective, is needed to inspire new insights and identify potential future opportunities for clinical pharmacologists to utilize RWD/RWE to address key drug development questions. In this paper, we review the RWD/RWE applications relevant to clinical pharmacology based on recent publications from member companies in the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) RWD Working Group, and discuss the future direction of RWE utilization from a clinical pharmacology perspective. A comprehensive review of RWD/RWE use cases is provided and discussed in the following categories of application: drug-drug interaction assessments, dose recommendation for patients with organ impairment, pediatric plan development and study design, model-informed drug development (e.g., disease progression modeling), prognostic and predictive biomarkers/factors identification, regulatory decisions support (e.g., label expansion), and synthetic/external control generation for rare diseases. Additionally, we describe and discuss common sources of RWD to help guide appropriate data selection to address questions pertaining to clinical pharmacology in drug development and regulatory decision making.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Zhu, R., Vora, B., Menon, S. S., Younis, I. R., Dwivedi, G., Meng, Z., Datta‐Mannan, A., Manchandani, P., Nayak, S., Tammara, B. K., Garhyan, P., Iqbal, S., Dagenais, S., Chanu, P., Mukherjee, A., & Ghobadi, C. (2023). Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective. Clinical Pharmacology & Therapeutics, 114(4), 751–767. https://doi.org/10.1002/cpt.2988
MLA 9
Zhu, Rui, et al. “Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective.” Clinical Pharmacology & Therapeutics, vol. 114, no. 4, 2023, pp. 751–767. https://doi.org/10.1002/cpt.2988.
Chicago
Zhu, Rui, Bianca Vora, Sujatha S. Menon, Islam Rasem Younis, Gaurav Dwivedi, Zhaoling Meng, Amita Datta‐Mannan, et al. 2023. “Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective.” Clinical Pharmacology & Therapeutics 114 (4): 751–767. https://doi.org/10.1002/cpt.2988.
Harvard
Zhu, R. et al. (2023) ‘Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective’, Clinical Pharmacology & Therapeutics, 114(4), pp. 751–767. doi:10.1002/cpt.2988.
IEEE
R. Zhu et al., “Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective,” Clinical Pharmacology & Therapeutics, vol. 114, no. 4, pp. 751–767, 2023, doi: 10.1002/cpt.2988.
BibTeX
@article{zhu2023clinical,
title = {{Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective}},
author = {Zhu, Rui and Vora, Bianca and Menon, Sujatha S. and Younis, Islam Rasem and Dwivedi, Gaurav and Meng, Zhaoling and Datta‐Mannan, Amita and Manchandani, Pooja and Nayak, Satyaprakash and Tammara, Brinda K. and Garhyan, Parag and Iqbal, Shahed and Dagenais, Simon and Chanu, Pascal and Mukherjee, Arnab and Ghobadi, Cyrus},
journal = {Clinical Pharmacology \& Therapeutics},
year = {2023},
volume = {114},
number = {4},
pages = {751--767},
doi = {10.1002/cpt.2988},
url = {https://doi.org/10.1002/cpt.2988}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 1 | |
| 2023 | 3 | |
| 2024 | 16 | |
| 2025 | 14 | |
| 2026 | 17 |
Its field-weighted citation impact is 2.20: it has been cited 2.20 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- real-world data
- real-world evidence
- clinical pharmacology
- drug development
- drug approval
- 21st Century Cures Act
- drug-drug interactions
- pediatric drug development
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Zhu, R., Vora, B., Menon, S. S., Younis, I. R., Dwivedi, G., Meng, Z., Datta‐Mannan, A., Manchandani, P., Nayak, S., Tammara, B. K., Garhyan, P., Iqbal, S., Dagenais, S., Chanu, P., Mukherjee, A., & Ghobadi, C. (2023). Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective. Clinical Pharmacology & Therapeutics, 114(4), 751–767. https://doi.org/10.1002/cpt.2988
How many times has this paper been cited?
51 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.
Who wrote this paper?
Rui Zhu, Bianca Vora, Sujatha S. Menon, Islam Rasem Younis, Gaurav Dwivedi, Zhaoling Meng, Amita Datta‐Mannan, Pooja Manchandani, Satyaprakash Nayak, Brinda K. Tammara, Parag Garhyan, Shahed Iqbal and 4 more.
What is the DOI of this paper?
10.1002/cpt.2988, permanently at https://doi.org/10.1002/cpt.2988. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.